Analysed EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) News Sources
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
21-04-2026
yahoo.com
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
05-05-2026
yahoo.com
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
06-05-2026
yahoo.com
What is the current price of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?
The current price of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is $6.4.
EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) since the previous trading day is $0.37.
EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) since the previous trading day is 6.136%.
What is the most recent average sentiment score for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?
The most recent average sentiment score for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?
The most recent sentiment for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is .
SEC-8K** Filing Available For EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.